Pharma Mergers, Acquisitions Signal Underlying Shift In Drug Development

A slew of recent mergers and acquisitions in the brand-name pharmaceutical industry, with more expected to come, highlights the changing dynamic in drug development, as companies realign their business strategies to better reflect the competitive environment and focus on differentiated products for which payers are willing to pay a premium, key industry analysts say. The market shift comes as Congress seeks to speed drug innovation by reforming FDA and boosting NIH, and the pharmaceutical industry simultaneously faces growing criticism over...